GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Patients with generalized pustular psoriasis had a reduction in pustules and increased skin clearance ...

Imsidolimab is a humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor. Treatment with imsidolimab led to significant clearance of pustulation, erythema, and scaling in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Spesolimab exhibited rapid control of generalized ...

A retrospective US claims study found that adults with generalized pustular psoriasis (GPP) had significantly more healthcare visits and costs than patients with plaque psoriasis alone. Researchers ...

An international consensus statement on generalized pustular psoriasis (GPP) from the International Psoriasis Council (IPC) includes the recommendation that considerations such as body surface area ...

Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...

In 1910, Leo Ritter von Zumbusch meticulously detailed the clinical course of "psoriasis pustulosa generalisata" (referred to herein as generalized pustular psoriasis, GPP) in a brother and sister, ...

An international panel of more than 30 experts has developed a consensus definition and diagnostic criteria for generalized pustular psoriasis (GPP). The new definition, published in JAMA Dermatology, ...

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...

INGELHEIM, Germany--(BUSINESS WIRE)--Today, at the 25 th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab ...